Tonix Pharmaceuticals Publishes Mpox Research Supporting TNX-801 Vaccine Development

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced the publication of new preclinical research in the Journal of Virology that demonstrates significant differences in virulence between mpox virus clade IIb, the strain currently circulating in the United States, and the historic clade IIa strain. The study, conducted at the company's research and development center, introduces three new mouse models for investigating mpox pathogenesis and found that the clade IIb isolate is up to 100,000 times less virulent than clade IIa. These findings provide additional tools to evaluate vaccines and other medical countermeasures against mpox.

The research supports the continued development of TNX-801, Tonix's live attenuated horsepox virus vaccine candidate for the prevention of mpox and smallpox. The company believes the new animal models will help researchers better understand emerging mpox variants, assess vaccine durability and protective efficacy, and advance efforts to address the ongoing global threat posed by the disease. The full press release can be accessed at https://ibn.fm/ZlMkM.

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's CNS portfolio includes TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), recently approved for fibromyalgia, as well as acute migraine products Zembrace SymTouch and Tosymra. Tonix is also advancing TNX-2900 for Prader-Willi syndrome and immunology programs including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection.

The latest news and updates regarding Tonix Pharmaceuticals are available in the company's newsroom at https://ibn.fm/TNXP. This research is critical as it provides new insights into mpox virulence and supports the development of a vaccine that could address both mpox and smallpox, diseases that remain global health threats.